Peer Review History

Original SubmissionJuly 17, 2025
Decision Letter - Peng Gao, Editor

PONE-D-25-37026Validation of blue- and clear-native polyacrylamide gel electrophoresis protocols to characterize mitochondrial oxidative phosphorylation complexesPLOS ONE

Dear Dr. Taanman,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Sep 19 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Peng Gao, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

3. To comply with PLOS One submissions requirements, in your Methods section, please provide additional information regarding the experiments involving animals and ensure you have included details on (1) methods of sacrifice, (2) methods of anesthesia and/or analgesia, and (3) efforts to alleviate suffering.

4. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript.

5. Please note that funding information should not appear in any section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript.

6. Please amend your list of authors on the manuscript to ensure that each author is linked to an affiliation. Authors’ affiliations should reflect the institution where the work was done (if authors moved subsequently, you can also list the new affiliation stating “current affiliation:….” as necessary).

7. Your abstract cannot contain citations. Please only include citations in the body text of the manuscript, and ensure that they remain in ascending numerical order on first mention.

8. Please remove all personal information, ensure that the data shared are in accordance with participant consent, and re-upload a fully anonymized data set.

Note: spreadsheet columns with personal information must be removed and not hidden as all hidden columns will appear in the published file.

Additional guidance on preparing raw data for publication can be found in our Data Policy (https://journals.plos.org/plosone/s/data-availability#loc-human-research-participant-data-and-other-sensitive-data) and in the following article: http://www.bmj.com/content/340/bmj.c181.long.

9. We note you have not yet provided a protocols.io PDF version of your protocol and/or a protocols.io DOI. When you submit your revision, please provide a PDF version of your protocol as generated by protocols.io (the file will have the protocols.io logo in the upper right corner of the first page) as a Supporting Information file. The filename should be S1_file.pdf, and you should enter “S1 File” into the Description field. Any additional protocols should be numbered S2, S3, and so on. Please also follow the instructions for Supporting Information captions [https://journals.plos.org/plosone/s/supporting-information#loc-captions]. The title in the caption should read: “Step-by-step protocol, also available on protocols.io.”

Please assign your protocol a protocols.io DOI, if you have not already done so, and include the following line in the Materials and Methods section of your manuscript: “The protocol described in this peer-reviewed article is published on protocols.io (https://dx.doi.org/10.17504/protocols.io.[...]) and is included for printing purposes as S1 File.” You should also supply the DOI in the Protocols.io DOI field of the submission form when you submit your revision.

If you have not yet uploaded your protocol to protocols.io, you are invited to use the platform’s protocol entry service [https://www.protocols.io/we-enter-protocols] for doing so, at no charge. Through this service, the team at protocols.io will enter your protocol for you and format it in a way that takes advantage of the platform’s features. When submitting your protocol to the protocol entry service please include the customer code PLOS2022 in the Note field and indicate that your protocol is associated with a PLOS ONE Lab Protocol Submission. You should also include the title and manuscript number of your PLOS ONE submission.

10. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 

11. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript report a protocol which is of utility to the research community and adds value to the published literature?

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the protocol been described in sufficient detail?

To answer this question, please click the link to protocols.io in the Materials and Methods section of the manuscript (if a link has been provided) or consult the step-by-step protocol in the Supporting Information files.

The step-by-step protocol should contain sufficient detail for another researcher to be able to reproduce all experiments and analyses.

Reviewer #1: Partly

Reviewer #2: Yes

**********

3. Does the protocol describe a validated method?

The manuscript must demonstrate that the protocol achieves its intended purpose: either by containing appropriate validation data, or referencing at least one original research article in which the protocol was used to generate data.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. If the manuscript contains new data, have the authors made this data fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the article presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please highlight any specific errors that need correcting in the box below.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The study presents a comprehensive validation of BN-PAGE and CN-PAGE protocols for characterizing OXPHOS complexes, with rigorous experimental design and robust supporting data. The following points should be addressed:

1.The authors should provide an explanation for the observed enhanced Complex IV staining in liver mitochondria relative to cultured cells. Given the liver's well-established high mitochondrial density and elevated metabolic activity, these inherent biological characteristics likely contribute to the differential staining outcomes. Clarification of this relationship would facilitate proper interpretation of the tissue-specific results.

2.For the technical limitations regarding Complex III/IV staining, additional discussion of potential underlying factors (e.g., enzyme stability or detergent compatibility) and attempted optimization strategies would strengthen the methodology section.

3.The wide range of protein loading quantities (5-30 μg) warrants clearer justification, especially whether this reflects biological sample differences or stain-specific sensitivity requirements.

4.The protocol's innovative aspects - particularly the streamlined extraction and enhanced Complex V detection - should be more prominently featured with direct comparisons to conventional methods.

5. Please discuss the similarities, differences, and innovations of this study in comparison to the referenced work (DOI: 10.3791/59294), particularly focusing on methodological advancements and biological implications.

6.Finally, a brief discussion of potential clinical applications, especially for mitochondrial disorder diagnostics, and sample-specific adaptation considerations would enhance the paper's translational impact.

Reviewer #2: This article validates a blue and transparent natural polyacrylamide gel electrophoresis (BN-PAGE and CN-PAGE) protocol for characterizing mitochondrial oxidative phosphorylation complexes. The study clearly describes the experimental protocol and provides sufficient experimental data to support its conclusions. This research has potential practical value as it simplifies the analysis process of mitochondrial oxidative phosphorylation complexes and enhances the sensitivity of certain enzyme activity staining.

Here are two suggestions:

1. The results section can be more concise and clear. For example, the description of the Western blot results can be simplified, with a focus on highlighting the key findings.

2. The discussion section can also explore the application prospects of this protocol in future research. For instance, it can discuss the potential applications of this protocol in diagnosing mitochondrial diseases and studying the effects of drugs on the OXPHOS system.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

Revision 1

Dr Peng Gao, Editor ─ PLOS ONE

12 August 2025

Dear Dr Gao,

Re: Validation of blue- and clear-native polyacrylamide gel electrophoresis protocols to characterize mitochondrial oxidative phosphorylation complexes (re-submission)

We thank you for your time and consideration concerning our manuscript. We thank you for sending us the constructive comments from the two reviewers and giving us the opportunity to address their concerns.

We hope that our revised manuscript is now acceptable for publication in PLOS ONE.

As suggested, regarding the experiments involving animals, we have now included details on (1) methods of sacrifice, (2) methods of anesthesia and (3) efforts to alleviate suffering.

Reviewer #1:

The study presents a comprehensive validation of BN-PAGE and CN-PAGE protocols for characterizing OXPHOS complexes, with rigorous experimental design and robust supporting data. The following points should be addressed:

We thank Reviewer 1 for the time and consideration to review our manuscript.

1. The authors should provide an explanation for the observed enhanced Complex IV staining in liver mitochondria relative to cultured cells. Given the liver's well-established high mitochondrial density and elevated metabolic activity, these inherent biological characteristics likely contribute to the differential staining outcomes. Clarification of this relationship would facilitate proper interpretation of the tissue-specific results.

We have now provided an explanation for the observed enhanced Complex IV staining in liver mitochondria relative to cultured cells in the Discussion, as suggested by Reviewer 1.

2. For the technical limitations regarding Complex III/IV staining, additional discussion of potential underlying factors (e.g., enzyme stability or detergent compatibility) and attempted optimization strategies would strengthen the methodology section.

We explain in the text that in-gel Complex IV activity staining is not particularly sensitive and that differences in OXPHOS enzyme content in the liver mitochondrial samples relative to the whole cell extract samples are likely to explain the inability to detect Complex IV activity by in-gel staining. We mention in the text that also others [22,42] have been unable to stain gels with cultured cell fractions for Complex IV activity in a conclusive manner.

To our knowledge, only one paper has claimed to achieve in-gel Complex III activity staining [21]. The authors used a bovine heart mitochondrial sample and incubated the gel in 0.5 mg/ml of diaminobenzidine (DAB) in 50 mM sodium phosphate (pH 7.2). No explanation is given why this incubation should result in a specific Complex III staining. Possibly, a peroxidase comigrating with Complex III oxidizes DAB, producing a brown indamine polymer. We have attempted to stain gels for Complex III with DAB but this did not result in any staining.

3. The wide range of protein loading quantities (5-30 μg) warrants clearer justification, especially whether this reflects biological sample differences or stain-specific sensitivity requirements.

We have now added a paragraph to the Discussion, which discusses protein loading quantities.

4. The protocol's innovative aspects - particularly the streamlined extraction and enhanced Complex V detection - should be more prominently featured with direct comparisons to conventional methods.

We have now mentioned the innovative streamlined extraction and enhanced Complex V detection in the first paragraph of the Discussion.

5. Please discuss the similarities, differences, and innovations of this study in comparison to the referenced work (DOI: 10.3791/59294), particularly focusing on methodological advancements and biological implications.

We have now included the paper by Cuillerier & Burelle (DOI: 10.3791/59294) in our References ([14]) and refer to it in the manuscript twice.

6. Finally, a brief discussion of potential clinical applications, especially for mitochondrial disorder diagnostics, and sample-specific adaptation considerations would enhance the paper's translational impact.

We have now added an extra paragraph at the end of the Discussion to discuss the potential applications of this protocol in diagnosing mitochondrial diseases and studying the effects of drugs on the OXPHOS system.

Reviewer #2: This article validates a blue and transparent natural polyacrylamide gel electrophoresis (BN-PAGE and CN-PAGE) protocol for characterizing mitochondrial oxidative phosphorylation complexes. The study clearly describes the experimental protocol and provides sufficient experimental data to support its conclusions. This research has potential practical value as it simplifies the analysis process of mitochondrial oxidative phosphorylation complexes and enhances the sensitivity of certain enzyme activity staining.

Here are two suggestions:

We thank Reviewer 2 for the time and consideration to review our manuscript.

1. The results section can be more concise and clear. For example, the description of the Western blot results can be simplified, with a focus on highlighting the key findings.

As this is a “Lab Protocol Article”, we feel that a thorough description of the results is needed for those who are new to the technique.

2. The discussion section can also explore the application prospects of this protocol in future research. For instance, it can discuss the potential applications of this protocol in diagnosing mitochondrial diseases and studying the effects of drugs on the OXPHOS system.

We have now added an extra paragraph at the end of the Discussion to discuss the potential applications of this protocol in diagnosing mitochondrial diseases and studying the effects of drugs on the OXPHOS system.

On behalf of all authors.

Yours faithfully,

Jan-Willem Taanman, PhD

Associate Professor of Clinical Neurosciences

Attachments
Attachment
Submitted filename: Response to reviewers.pdf
Decision Letter - Peng Gao, Editor

Validation of blue- and clear-native polyacrylamide gel electrophoresis protocols to characterize mitochondrial oxidative phosphorylation complexes

PONE-D-25-37026R1

Dear Dr. Taanman,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support .

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Peng Gao, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript report a protocol which is of utility to the research community and adds value to the published literature?

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the protocol been described in sufficient detail?

To answer this question, please click the link to protocols.io in the Materials and Methods section of the manuscript (if a link has been provided) or consult the step-by-step protocol in the Supporting Information files.

The step-by-step protocol should contain sufficient detail for another researcher to be able to reproduce all experiments and analyses.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Does the protocol describe a validated method?

The manuscript must demonstrate that the protocol achieves its intended purpose: either by containing appropriate validation data, or referencing at least one original research article in which the protocol was used to generate data.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. If the manuscript contains new data, have the authors made this data fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the article presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please highlight any specific errors that need correcting in the box below.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors have fully addressed and supplemented the previous reviewer comments, and conducted in-depth discussions on the key issues raised.

Reviewer #2: This article validates a blue and transparent natural polyacrylamide gel

electrophoresis (BN-PAGE and CN-PAGE) protocol for characterizing mitochondrial

oxidative phosphorylation complexes. The study clearly describes the experimental

protocol and provides sufficient experimental data to support its conclusions. This

research has potential practical value as it simplifies the analysis process of

mitochondrial oxidative phosphorylation complexes and enhances the sensitivity of

certain enzyme activity staining.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: No

**********

Formally Accepted
Acceptance Letter - Peng Gao, Editor

PONE-D-25-37026R1

PLOS ONE

Dear Dr. Taanman,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Professor Peng Gao

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .